Biocon announces key data on Insulin Tregopil

Following Phase 1 Studies

Biocon announced key data on Insulin Tregopil (formerly referred to as IN-105) following Phase 1 studies that validate and provide the basis for the next phase of clinical development of this important molecule. The clinical studies on Insulin Tregopil, which were conducted in the US under a US IND, were initiated in partnership with Bristol-Myers Squibb prior to their disinvestment of the diabetes franchise to AstraZeneca.

Powered by Capital Market - Live News